NCT00725296View on ClinicalTrials.gov

Investigation of 9 Consecutive Infusions of Remicade for Psoriatic Arthritis in Austria (Study P04264)

CompletedOBSERVATIONAL
Enrollment

178

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions
Arthritis, Psoriatic
Interventions
BIOLOGICAL

Remicade (Infliximab)

Induction infusions of Remicade will be administered at weeks 0, 2, and 6 given in a dosage due to the decision of the physicians. A maximum of 6 maintenance infusions will be administered with the dosage and interval due to the discretion of the physicians.

Sponsors

Collaborators (1)

Centocor, Inc.
All Listed Sponsors
collaborator

Centocor, Inc.

INDUSTRY

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00725296 - Investigation of 9 Consecutive Infusions of Remicade for Psoriatic Arthritis in Austria (Study P04264) | Biotech Hunter | Biotech Hunter